Jeremy C. Jones, MD

Jeremy C. Jones, MD, discusses the applications of circulating tumor DNA testing in colorectal cancer.

Jeremy C. Jones, MD, discusses key lessons learned from the phase 3 KEYNOTE-177 trial.

Jeremy C. Jones, MD, discusses targeting HER2 alterations in colorectal cancer.

Jeremy C. Jones, MD, discusses the risk of interstitial lung disease with fam-trastuzumab deruxtecan-nxki in colorectal cancer.

Jeremy C. Jones, MD, discusses the clinical utility of pembrolizumab in microsatellite instability–high colorectal cancer.

Jeremy C. Jones, MD, discusses the importance of testing for microsatellite instability high in colorectal cancer.